Feb 07, 2024 / 01:00PM GMT
Operator
Good day, and welcome to Neurocrine Biosciences Year-End and Fourth Quarter Results Call. (Operator Instructions). Please note today's call will be recorded, and I'll be standing by if you should need any assistance.
It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Todd Tushla -
Thank you, and a good Wednesday morning to everyone. Welcome to Neurocrine Biosciences Fourth Quarter and Full Year 2023 Earnings Call. Joining us today are Kevin Gorman, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eiry Roberts, Chief Medical Officer; Eric Benevich, Chief Commercial Officer; and Kyle Gano, Chief Business Development and Strategy Officer.
During the call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. Today's prepared remarks will be a bit longer in duration versus prior earnings
Q4 2023 Neurocrine Biosciences Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot